Investigators propensity-score matched 546 users of erythropoietin, an erythropoiesis-stimulating agent (ESA), with 546 users of roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor ...

This included patients on dialysis, including both hemo- and peritoneal dialysis, and those not on dialysis, regardless of prior anaemia treatment with erythropoiesis-stimulating agents (ESAs ...